Helix Biopharma Corp.
HBP.TO
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 215.75% | 200.14% | 206.58% | 7.70% | -8.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.12% | 58.00% | 43.77% | 14.14% | 4.82% |
| Operating Income | -73.12% | -58.00% | -43.77% | -14.14% | -4.82% |
| Income Before Tax | -70.51% | -55.54% | -44.97% | -9.76% | 0.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.51% | -55.54% | -44.97% | -9.76% | 0.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.51% | -55.54% | -44.97% | -9.76% | 0.75% |
| EBIT | -73.12% | -58.00% | -43.77% | -14.14% | -4.82% |
| EBITDA | -73.32% | -58.13% | -43.85% | -14.12% | -4.80% |
| EPS Basic | -41.09% | -29.94% | -17.47% | 3.60% | 17.91% |
| Normalized Basic EPS | -41.28% | -29.81% | -17.45% | -7.52% | 9.45% |
| EPS Diluted | -61.64% | -29.94% | -17.47% | 3.60% | 17.91% |
| Normalized Diluted EPS | -41.28% | -29.81% | -17.45% | -7.52% | 9.45% |
| Average Basic Shares Outstanding | 17.83% | 14.40% | 15.98% | 12.93% | 19.69% |
| Average Diluted Shares Outstanding | 17.83% | 14.40% | 15.98% | 12.93% | 19.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |